PSTV Plus Therapeutics, Inc. Stock Quote

PSTV [NASD]

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	0.50%	Shs Outstand	13.26M	Perf Week	-5.66%
Market Cap	23.92M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	57.86%	Shs Float	12.04M	Perf Month	-12.28%
Income	-12.80M	PEG	-	EPS next Q	-0.24	Inst Own	8.50%	Short Float	0.49%	Perf Quarter	-20.63%
Sales	0.00M	P/S	-	EPS this Y	32.90%	Inst Trans	-18.56%	Short Ratio	0.05	Perf Half Y	-36.71%
Book/sh	1.11	P/B	1.35	EPS next Y	1.00%	ROA	-67.50%	Target Price	6.50	Perf Year	-29.25%
Cash/sh	1.34	P/C	1.12	EPS next 5Y	-	ROE	-130.80%	52W Range	1.42 - 5.42	Perf YTD	-25.74%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-103.10%	52W High	-72.32%	Beta	0.36
Dividend %	-	Quick Ratio	-	Sales past 5Y	-51.80%	Gross Margin	-	52W Low	5.63%	ATR	0.11
Employees	12	Current Ratio	2.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	31.81	Volatility	6.24% 6.34%
Optionable	No	Debt/Eq	0.46	EPS Q/Q	28.50%	Profit Margin	-	Rel Volume	0.03	Prev Close	1.53
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Oct 21 AMC	Payout	-	Avg Volume	1.23M	Price	1.50
Recom	2.00	SMA20	-12.69%	SMA50	-15.65%	SMA200	-32.89%	Volume	32,915	Change	-1.96%

Jan-25-21

Initiated

Ladenburg Thalmann

Buy

Oct-16-20

Initiated

Maxim Group

Buy

Nov-22-21 07:31AM	Is Plus Therapeutics (NASDAQ:PSTV) A Risky Investment? Simply Wall St.
Nov-18-21 02:18PM	Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial Benzinga
08:00AM	Plus Therapeutics Announces Positive Interim Data from ReSPECT-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting GlobeNewswire
Nov-12-21 07:30AM	Plus Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Nov-09-21 07:00AM	Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases GlobeNewswire
Nov-03-21 07:00AM	Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT-GBM Trial GlobeNewswire
Oct-29-21 10:04AM	3 Penny Stocks Insiders Are Buying Benzinga
Oct-27-21 02:00PM	Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting GlobeNewswire
Oct-21-21 04:05PM	Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Oct-19-21 07:30AM	Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases GlobeNewswire
Oct-14-21 07:30AM	Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021 GlobeNewswire
Sep-30-21 08:00AM	Plus Therapeutics to Present ReSPECT-GBM Clinical Trial Data at the 2021 SNO Annual Meeting GlobeNewswire
Sep-27-21 07:30AM	Plus Therapeutics to Present at the Benzinga Healthcare Small Cap Conference GlobeNewswire
Sep-23-21 07:30AM	Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting GlobeNewswire
Sep-13-21 07:00AM	Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Companys Chief Medical Officer GlobeNewswire
Sep-08-21 07:00AM	Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-02-21 07:00AM	Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug GlobeNewswire +7.89%
Aug-23-21 06:25AM	Why Is Plus Therapeutics Stock Rising After Data Presentation From Brain Tumor Trial? Benzinga
Aug-21-21 09:24AM	Plus Therapeutics Announces Presentation of Data from the ReSPECT-GBM Trial and Plans for Treating Pediatric Brain Cancer GlobeNewswire
Aug-19-21 08:13AM	Plus Therapeutics Shares Preclinical Data For Targeted Cancer Radiation Therapy: Highlights Benzinga -9.39%
07:00AM	Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial GlobeNewswire
Aug-13-21 07:51AM	Plus Therapeutics to Present Data from ReSPECT-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting GlobeNewswire
Aug-11-21 10:12AM	Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome GlobeNewswire +11.23%
Aug-05-21 07:30AM	Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Jul-27-21 07:00AM	Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement GlobeNewswire -10.55%
Jul-22-21 04:05PM	Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights GlobeNewswire
07:00AM	Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT-GBM Trial GlobeNewswire
Jul-15-21 07:30AM	Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021 GlobeNewswire
Jun-16-21 07:30AM	Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT Glioblastoma Trial GlobeNewswire
Jun-10-21 07:30AM	Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference GlobeNewswire
Jun-09-21 04:15PM	Plus Therapeutics to Participate in BIO Digital Conference GlobeNewswire
May-24-21 06:46AM	Is Plus Therapeutics (NASDAQ:PSTV) Weighed On By Its Debt Load? Simply Wall St. -6.25%
May-04-21 07:30AM	Plus Therapeutics Announces Key RNL Development and cGMP Drug Manufacturing Collaboration Agreements GlobeNewswire -7.69%
Apr-22-21 04:05PM	Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Apr-08-21 07:30AM	Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021 GlobeNewswire
Mar-23-21 07:30AM	Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization GlobeNewswire
Mar-18-21 08:30AM	Plus Therapeutics, Inc. to Participate in Upcoming Virtual Conferences GlobeNewswire
Mar-05-21 11:51AM	Insider Buys Plus Therapeutics Shares Benzinga +25.56%
Mar-04-21 11:04AM	Insider Buys Plus Therapeutics Stock Benzinga -7.08%
Mar-03-21 07:30AM	Plus Therapeutics to Participate in Upcoming Virtual Conferences GlobeNewswire -11.44%
Mar-02-21 07:30AM	Nextech Successfully Launches its Ad Network Featuring Augmented Reality Capabilities on its Virtual Events Properties, Delivering Millions of Impressions Business Wire
Mar-01-21 07:30AM	Nextech AR Solutions to Present at the Emerging Growth Conference on March 3, 2021 Business Wire -8.42%
07:30AM	Emerging Growth Conference 2 Announced for March 3, 2021 Niche Companies in Technology, AR, eCommerce, Beverage and more in Attendance GlobeNewswire
Feb-22-21 04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights GlobeNewswire
02:45PM	Plus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-11-21 04:15PM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021 GlobeNewswire -9.33%
07:30AM	Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference GlobeNewswire
Jan-11-21 10:11AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Jan-05-21 04:15PM	Plus Therapeutics to Participate in Upcoming January Conferences GlobeNewswire
Dec-15-20 07:30AM	Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT Glioblastoma Trial GlobeNewswire
Dec-08-20 07:30AM	Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference GlobeNewswire
Dec-01-20 07:30AM	Plus Therapeutics Expands ReSPECT Clinical Trial to MD Anderson Cancer Center GlobeNewswire
Nov-19-20 08:00AM	Plus Therapeutics Announces Positive Interim Data from ReSPECT Phase 1 Clinical Trial in Recurrent Glioblastoma GlobeNewswire -6.01%
Nov-16-20 08:00AM	Plus Therapeutics to Participate in Upcoming November Investor Conferences GlobeNewswire
Nov-13-20 07:30AM	Plus Therapeutics Announces Webinar to Present ReSPECT Glioblastoma Clinical Trial Update GlobeNewswire
Nov-12-20 07:25AM	Plus Therapeutics to Present at the virtual Fall Investor Summit on November 16th-18th ACCESSWIRE
Nov-05-20 07:00AM	Plus Therapeutics Announces Formation of Scientific Advisory Board GlobeNewswire
Oct-29-20 07:00AM	Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT Glioblastoma Trial GlobeNewswire
Oct-22-20 04:05PM	Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire +6.15%
03:00PM	Plus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-15-20 07:00AM	Plus Therapeutics to Present at the Cancer Innovation Summit GlobeNewswire
Oct-14-20 04:15PM	Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020 GlobeNewswire
Oct-02-20 07:00AM	Plus Therapeutics Announces Brain Cancer Clinical Advisory Team GlobeNewswire
Oct-01-20 07:00AM	ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting GlobeNewswire
Sep-15-20 07:00AM	Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment GlobeNewswire +24.18%
Sep-09-20 07:00PM	Plus Therapeutics, Inc. to Present at the 22nd H. C. Wainwright Annual Global Investor Conference on September 15, 2020 GlobeNewswire
Sep-03-20 07:00AM	Plus Therapeutics, Inc. to Present at the 9th Annual Gateway Conference on September 10, 2020 GlobeNewswire -7.37%
Sep-01-20 07:00AM	Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment GlobeNewswire +15.51%
Aug-28-20 07:00AM	Plus Therapeutics, Inc. to Present at The LD 500 Virtual Conference GlobeNewswire
Aug-25-20 10:31AM	How Much Did Plus Therapeutics' (NASDAQ:PSTV) CEO Pocket Last Year? Simply Wall St.
Aug-10-20 07:43AM	Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results GlobeNewswire -5.68%
Aug-03-20 07:00AM	Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020 GlobeNewswire +7.00%
Jul-28-20 07:00AM	Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT Glioblastoma Clinical Trial and Expands Trial Sites GlobeNewswire +7.91%
Jul-23-20 05:00PM	Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020 GlobeNewswire
Jul-06-20 08:01AM	Plus Therapeutics Announces Inducement Stock Grants GlobeNewswire +8.96%
May-14-20 04:27PM	Plus Therapeutics Reports First Quarter 2020 Financial and Business Results GlobeNewswire +17.69%
May-12-20 08:57AM	Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month GlobeNewswire +23.03%
May-11-20 06:00AM	Plus Therapeutics Announces Closing of Agreement To License Novel Oncology Platform GlobeNewswire
May-07-20 04:15PM	Plus Therapeutics To Report First Quarter Fiscal Year 2020 Financial Results and Corporate Update on May 14, 2020 GlobeNewswire
Apr-16-20 04:15PM	Plus Therapeutics to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 ACCESSWIRE -5.49%
Apr-06-20 07:00AM	Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic GlobeNewswire +10.49%
Apr-01-20 07:00AM	Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development GlobeNewswire -9.57%
Mar-30-20 04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Fiscal Year 2019 Financial and Business Results GlobeNewswire +57.64%
03:00PM	Plus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
07:15AM	Plus Therapeutics Licenses Novel Oncology Platform, Expands Pipeline GlobeNewswire
Mar-25-20 05:53PM	Plus Therapeutics To Report Fourth Quarter and Full Fiscal Year 2019 Financial Results and Corporate Update on March 30, 2020 GlobeNewswire +7.69%
Mar-12-20 07:15AM	Plus Therapeutics Welcomes Two New Directors GlobeNewswire -22.54%
Feb-06-20 05:00PM	Plus Therapeutics Appoints Chief Financial Officer GlobeNewswire
05:00PM	Plus Therapeutics Announces Changes to its Board of Directors GlobeNewswire
Jan-06-20 07:15AM	Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 GlobeNewswire
Jan-02-20 04:15PM	Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors GlobeNewswire +10.42%
Dec-09-19 07:00AM	Plus Therapeutics to Present at Biotech Showcase 2020 GlobeNewswire +7.42%
Nov-25-19 07:00AM	Plus Therapeutics to Present at the LD Micro Main Event (XII) GlobeNewswire
Nov-14-19 04:05PM	Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results GlobeNewswire
Nov-04-19 07:00AM	Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 GlobeNewswire
Oct-15-19 09:20AM	Plus Therapeutics Receives $4.6MM Reimbursement Payment GlobeNewswire +12.24%
Sep-26-19 04:10PM	Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering GlobeNewswire
Sep-23-19 12:15PM	Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering GlobeNewswire -49.50%
06:10AM	Plus Therapeutics to Receive $4.6MM Reimbursement Payment GlobeNewswire

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Nov 02	Buy	1.86	1,000	1,864	7,230	Nov 04 06:15 AM
Petersen Greg	Director	Oct 27	Buy	1.72	12,500	21,500	32,500	Oct 28 06:15 AM
HEDRICK MARC H	Chief Executive Officer	Oct 26	Buy	1.66	2,500	4,150	21,080	Oct 27 06:15 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Oct 26	Buy	1.67	2,000	3,339	6,230	Oct 27 06:15 AM
Lenk Robert P	Director	Sep 13	Buy	1.86	7,000	13,011	10,000	Sep 15 07:30 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Jul 28	Buy	1.91	2,244	4,286	4,230	Jul 29 06:35 PM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Jul 27	Buy	2.05	1,986	4,071	1,986	Jul 29 06:35 PM
HEDRICK MARC H	Chief Executive Officer	Apr 30	Buy	2.28	2,183	4,970	18,580	May 03 06:15 AM
HEDRICK MARC H	Chief Executive Officer	Mar 04	Buy	2.50	2,500	6,250	16,397	Mar 05 06:15 AM
Clowes Howard	Director	Mar 03	Buy	2.42	3,000	7,260	3,000	Mar 04 06:15 AM
HEDRICK MARC H	Chief Executive Officer	Dec 10	Buy	1.99	2,500	4,975	13,867	Dec 14 06:05 AM
HEDRICK MARC H	Chief Executive Officer	Nov 30	Buy	2.14	2,200	4,708	11,367	Dec 02 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience